Iovance Biotherapeutics Inc (NASDAQ:IOVA) has been given a consensus recommendation of “Buy” by the ten ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $25.00.

Several equities analysts have recently weighed in on the company. Chardan Capital reissued a “buy” rating and set a $20.00 price target on shares of Iovance Biotherapeutics in a report on Tuesday, April 2nd. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Iovance Biotherapeutics in a report on Monday, April 1st. BidaskClub raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 4th. Zacks Investment Research cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 15th. Finally, ValuEngine cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Iovance Biotherapeutics by 66.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,374 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 6,162 shares during the period. RA Capital Management LLC raised its holdings in Iovance Biotherapeutics by 142.6% in the 4th quarter. RA Capital Management LLC now owns 2,720,452 shares of the biotechnology company’s stock worth $24,076,000 after purchasing an additional 1,599,299 shares during the period. NF Trinity Capital Hong Kong Ltd raised its holdings in Iovance Biotherapeutics by 83.0% in the 4th quarter. NF Trinity Capital Hong Kong Ltd now owns 228,442 shares of the biotechnology company’s stock worth $2,022,000 after purchasing an additional 103,588 shares during the period. Vanguard Group Inc raised its holdings in Iovance Biotherapeutics by 8.1% in the 3rd quarter. Vanguard Group Inc now owns 4,048,782 shares of the biotechnology company’s stock worth $45,550,000 after purchasing an additional 302,649 shares during the period. Finally, Teachers Advisors LLC raised its holdings in Iovance Biotherapeutics by 27.6% in the 3rd quarter. Teachers Advisors LLC now owns 727,043 shares of the biotechnology company’s stock worth $8,179,000 after purchasing an additional 157,427 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

IOVA stock opened at $10.84 on Monday. The company has a market capitalization of $1.34 billion, a P/E ratio of -8.54 and a beta of 1.91. Iovance Biotherapeutics has a 12-month low of $7.26 and a 12-month high of $18.25.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: What Does Beta Mean In Stock Selection

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.